Amid heightened scrutiny of pharmaceutical industry practices, Canadian authorities have decided that Johnson & Johnson (JNJ) did not take any illegal action to thwart biosimilar competition for its best-selling Remicade medicine.

The decision comes as a growing number of countries struggling to contain the rising cost of medicines examine steps taken by drug makers to boost market share. The ruling also arrives as J&J fends off a closely watched lawsuit filed in the U.S. by Pfizer (PFE) over claims that J&J engaged in anti-competitive behavior to stifle a biosimilar version of Remicade.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy